806 related articles for article (PubMed ID: 17289685)
1. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
Campbell IA; Bentley DP; Prescott RJ; Routledge PA; Shetty HG; Williamson IJ
BMJ; 2007 Mar; 334(7595):674. PubMed ID: 17289685
[TBL] [Abstract][Full Text] [Related]
2. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
[TBL] [Abstract][Full Text] [Related]
3. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
4. Six months
Couturaud F; Pernod G; Presles E; Duhamel E; Jego P; Provost K; Pan-Petesch B; Sollier CBD; Tromeur C; Hoffmann C; Bressollette L; Lorillon P; Girard P; Le Moigne E; Le Hir A; Guégan M; Laporte S; Mismetti P; Lacut K; Bosson JL; Bertoletti L; Sanchez O; Meyer G; Leroyer C; Mottier D;
Haematologica; 2019 Jul; 104(7):1493-1501. PubMed ID: 30606789
[TBL] [Abstract][Full Text] [Related]
5. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
6. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
8. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
9. Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study.
Vucić N; Ostojić R; Svircić T
Croat Med J; 2002 Jun; 43(3):296-300. PubMed ID: 12035135
[TBL] [Abstract][Full Text] [Related]
10. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.
Lancet; 1992 Oct; 340(8824):873-6. PubMed ID: 1357297
[TBL] [Abstract][Full Text] [Related]
11. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
[TBL] [Abstract][Full Text] [Related]
13. Early follow-up and treatment recommendations for isolated calf deep venous thrombosis.
Singh K; Yakoub D; Giangola P; DeCicca M; Patel CA; Marzouk F; Giangola G
J Vasc Surg; 2012 Jan; 55(1):136-40. PubMed ID: 21982332
[TBL] [Abstract][Full Text] [Related]
14. Extended oral anticoagulant therapy after a first episode of pulmonary embolism.
Agnelli G; Prandoni P; Becattini C; Silingardi M; Taliani MR; Miccio M; Imberti D; Poggio R; Ageno W; Pogliani E; Porro F; Zonzin P;
Ann Intern Med; 2003 Jul; 139(1):19-25. PubMed ID: 12834314
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Pinede L, Ninet J, Duhaut P et al for the Investigators of the 'Durée Optimale du Traitement Antivitamines K' (DOTAVK) study. Circulation 2001; 103: 2453-60.
Anand SS
Vasc Med; 2001 Nov; 6(4):269-70. PubMed ID: 11958396
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
Farraj RS
Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
[TBL] [Abstract][Full Text] [Related]
17. [Is a three-month therapy with warfarin adequate for effective therapy of patients after an episode of venous thrombosis].
Vorob'eva NM; Ermolina OV; Balakhonova TV; Dobrovol'skiĭ AB; Titaeva EV; Kirienko AI; Panchenko EP
Ter Arkh; 2008; 80(7):50-4. PubMed ID: 18763596
[TBL] [Abstract][Full Text] [Related]
18. D-dimer testing to determine the duration of anticoagulation therapy.
Palareti G; Cosmi B; Legnani C; Tosetto A; Brusi C; Iorio A; Pengo V; Ghirarduzzi A; Pattacini C; Testa S; Lensing AW; Tripodi A;
N Engl J Med; 2006 Oct; 355(17):1780-9. PubMed ID: 17065639
[TBL] [Abstract][Full Text] [Related]
19. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
